There is growing evidence that CD4+ CD5+ Treg cells may play an important role in suppressing the development of antitumor immunity in cancer patients [51] and that the number of Treg cells is increased in tumor sites and/or the peripheral blood of patients with advanced tumors [52–54]. This evidence concerns the gene CD4 and neoplasm.